#ThinkSabio Latest News

Lexeo therapeutics provides update on cardiac portfolio and reports third quarter 2024 financial results, qtrly net loss $0.89 per share, believes cash and cash equivalents as of Sept 30 will be sufficient to fund operations into 2027